TABLE 3.

Antimalarial activity of compound 5f against an MDR P. yoelii strain in vivo in a mouse model^a

Compound	Dose (mg/kg)	Mean % parasitemia ± SD				Mean % parasitemia suppression ± SDb	Survival rate
		Day 2	Day 4	Day 6	Day 7
Control		2.5 ± 0.3	13.3 ± 2.2	42.5 ± 4.5	58.6 ± 9.5	0	0/6
5f	10	3.5 ± 1.1	15.8 ± 0.9	28.7 ± 2.9	40.3 ± 3.3	31.2 ± 3.6	0/6
	25	2.8 ± 0.8	14.9 ± 1.9	18.6 ± 3.1	24.8 ± 2.6	57.7 ± 6.4	2/6
	50	2.6 ± 1.3	14.1 ± 1.4	12.6 ± 3.1	14.8 ± 2.6	74.7 ± 8.3	5/6
α/β arteether		3.2 ± 0.4	14.2 ± 1.4	6.5 ± 0.7	0	100	6/6

^aSwiss albino mice (six mice in each group) were infected by an MDR P. yoelii strain (i.e., resistant to chloroquine, mefloquine, and halofantrine) and treated with compound 5f (at 10, 25, and 50 mg/kg [body weight]) from days 4 to 7 intraperitoneally, and the parasitemia was monitored over time.

^bThe percent parasitemia suppression at day 7 was calculated as follows: [(C − T)/C] × 100, where C is the parasitemia in the control group and T is the parasitemia in the treated group. The data represent the means ± SD (n = 6). The survival number was determined at day 10 (in the control group, all of the mice were dead at day 7).